Home Newsletter Honored Guests Blog About Us Work With Us Sponsor & Advertise Be a Guest The Production Suite Get the Briefing

Open Door Salon

Clinton West

Clinton West

President, Supply Chain Security, Aardwolf Global Solutions | Former CIA Supply-Chain Risk Leader

Clinton West is the president of the supply chain security practice at Aardwolf Global Solutions, where he leads intelligence-driven work to secure critical supply chains for national-security, defense, and commercial operations. He spent more than two decades at the Central Intelligence Agency, with earlier service in the US Navy and the National Reconnaissance Office. At the CIA he led the Office of Supply Chain Risk Management and held senior supply-chain and risk roles across Europe, Africa, and the Middle East.

West appeared on Open Door Salon alongside Mike Walker, a health-and-life-sciences digital-strategy leader, for a conversation on cybersecurity and the security of the pharmaceutical supply chain. Drawing on his intelligence career, West argued that the conflict in the Middle East exposed a strategic shift: Iran moving to close the Strait of Hormuz is something the CIA long anticipated but had never seen attempted.

His central warning was about dependency. Pharmaceutical companies, he said, built their supply chains for resilience, but only at the level of visible, surface-level products, not the downstream dependencies that actually carry the risk: the roughly 70 percent of active pharmaceutical ingredients sourced from India and China, and the energy and semiconductor supply chains that everything else rests on.

This disruption, West argued, is different from the 2008 financial crisis or the COVID shock, because adversaries are now studying supply chains with precision, looking specifically for the break points. It is a game, he said, that brittle, linear supply chains were never architected to withstand, and his work with companies is now a race to map their true dependencies and build optionality before the next disruption.

On Open Door Salon

“Cyberattacks and Closed Straits — Defending Pharma on Two Fronts”
Clinton West & Mike Walker · May 13, 2026

Episode page & show notes on Open Door Salon

“Iran has always been an adversary, but never have we seen an opportunity like the one they've taken to close the straits. It's always been on the minds of the CIA and the Department of War, but now it's actually happening.”Clinton West, on Open Door Salon (on the strategic shift at the Strait of Hormuz)
“Pharma built their supply chains for resilience, but that was visibility of the surface-level products, not the downstream dependencies — not the 70% of API that comes from India and China.”Clinton West, on Open Door Salon (on the blind spot in pharma supply chains)
“This disruption is different from 2008 or COVID: you have adversaries looking at your supply chain with precision, finding the break points. It's a much different game than our supply chains were architected for.”Clinton West, on Open Door Salon (on adversaries targeting supply-chain break points)

In this episode

  • What the Iran conflict revealed about pharma supply chains
  • The Strait of Hormuz: long anticipated, now attempted
  • Energy as the supply chain beneath all supply chains
  • 70% of API comes from India and China
  • Built for resilience, blind to dependencies
  • Adversaries targeting break points with precision
  • From linear and brittle to optionality
  • Mapping the true downstream dependencies

Topics

Supply Chain SecuritySupply Chain RiskPharmaceutical Supply ChainNational SecurityGeopolitical RiskIntelligenceCybersecurityAPI SourcingResilienceEnergy Supply Chain

Watch on Open Door Salon

Cyberattacks and Closed Straits — Defending Pharma on Two Fronts | Clinton West & Mike Walker

Open Door Salon brings life-sciences leaders into candid conversation. Every Monday, the week's takeaways land in your inbox.

Subscribe on Substack →
The Briefing

Need the life-sciences signal but short on time?

Get a free quarterly briefing: four pages on what life-sciences operators are actually saying about Biosecure, AI hype vs. substance, and the $50,000 cell-therapy question. Ten minutes, in your inbox.